Helicobacter pylori (H. pylori) infected patients have a high-risk of developing stomach cancer and gastroduodenal ulcers. Eradication therapy is recommended because gastritis improves by eradicating H. pylori. We assessed the factors influencing eradication therapy. In the eradication success group, the percentage of treatments using vonoprazan (VPZ) was significantly higher than in the eradication failure group (odds ratio 4.71, P < 0.01). Chronic gastritis (odds ratio 1.04, P < 0.01) and gastroduodenal ulcers (odds ratio 2.76, P < 0.01) were found to be important factors influencing eradication. The eradication rates of chronic gastritis were lansoprazole (LPZ): 76％, rabeprazole (RPZ): 73％, esomeprazole (EPZ): 79％, and VPZ: 96％. VPZ had a high eradication rate, significantly more than that of LPZ, RPZ, and EPZ. The eradication rates of gastroduodenal ulcers were LPZ: 89％, RPZ: 91％, EPZ: 89％, and VPZ: 96％, and there were no significant differences. VPZ demonstrated a high eradication rate (96％) of chronic gastritis and gastroduodenal ulcers. Our results confirm that VPZ is more effective in eradication therapy than LPZ, RPZ, and EPZ. LPZ is expensive for eradicating chronic gastritis, and EPZ is relatively cheap. On the other hand, VPZ is expensive for eradicating gastroduodenal ulcers, and RPZ is relatively cheap. We think that it is important to consider which disease is being targeted when choosing the medicine for eradicating H. pylori.